Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Coombs on the Ongoing Investigation of Quizartinib in AML

April 22nd 2024

Catherine C. Coombs, MD, discusses the efficacy of the FLT3 inhibitor quizartinib in acute myeloid leukemia.

FDA Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML

April 22nd 2024

The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.

Dr Castillo on the Rationale for Evaluating Iopofosine I 131 in Waldenström Macroglobulinemia

April 19th 2024

Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.

Dr Coombs on Disease Management Strategies in AML

April 18th 2024

Catherine C. Coombs, MD, discusses strategies for disease classification and management for patients with acute myeloid leukemia.

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

April 18th 2024

Experts discuss the FDA's call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.

EMA Grants Orphan Drug Designation to Annamycin in AML

April 18th 2024

The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.

State of the Science Summit - Hematologic Malignancies: Chaired by Rebecca Klisovic, MD

April 18th 2024

State of the Science Summit - Hematologic Malignancies: Chaired by Rebecca Klisovic, MD

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

April 17th 2024

Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.

FDA Grants Orphan Drug Designation to BVX001 in AML

April 17th 2024

BVX001 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.

Dr Ferrajoli on Shared Decision-Making During BTK Inhibitor Selection in Hematologic Malignancies

April 15th 2024

Alessandra Ferrajoli, MD, discusses the importance of shared decision-making when considering the use of BTK inhibitors in hematologic malignancies.

Orca-T May Be a Suitable Option Over PTCy-Based HSCT in Acute Leukemia and MDS

April 15th 2024

Orca-T demonstrated positive impacts on relapse-free survival and overall survival vs PTCy-based HSCT in acute leukemias and myelodysplastic syndrome.

Orca-T Proves Safe and Effective in Advanced Hematologic Malignancies

April 15th 2024

The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.

MRD-Negative CR Separates Ponatinib From the Rest in Newly Diagnosed, Ph+ ALL

April 15th 2024

Ibrahim Aldoss, MD, discusses the FDA approval of ponatinib plus chemotherapy in newly diagnosed, Ph-positive acute lymphoblastic leukemia.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

RGI-2001 Plus Tacrolimus/Methotrexate Demonstrates Protective Effect From Acute GVHD Post Allo-HSCT

April 10th 2024

Prophylactic treatment with RGI-2001 plus tacrolimus and methotrexate led to a lower incidence of acute GVHD vs CIBMTR control following allo-HSCT.

FDA Grants Fast Track Designation to Tamibarotene/Azacitidine/Venetoclax for RARA-Overexpressed AML

April 10th 2024

Tamibarotene plus azacitidine and venetoclax has received FDA fast track designation for newly diagnosed, unfit, RARA-overexpressed AML.

Emerging Treatments for Myelofibrosis

April 10th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further.